 |
 |
|
|
|
|
We continue to invest heavily in
new technologies. Transactions such as
these open the way to developing
new and better diagnostic tests and
treatments for complex diseases.
November/December 2008
The industry started feeling the pinch of belt-tightening almost a decade ago, slowly at first. But today’s pressures must feel like a vise grip. Being squeezed from all sides, life-sciences companies are having to counter multiple challenges of tremendous magnitude: increased regulatory scrutiny, the need to control costs, generic competition, pricing pressures, and reputation management, to name just a few. Historically slow to change course, but with a world of new obstacles to navigate, the industry will need to transform itself into a more nimble, forward-thinking, patient-centric entity.
  |
|
|
|
|
|
 Ken Ribotsky
Core-Create
Regulating bodies, both government and industry, must realize that the train has already left the station,” he says. “It is simply irresponsible not to allow manufacturers and brand teams to be part of a machine that provides the opportunity to disseminate quality information, as well as to correct misinformation, in real time. 
|
MaryAnn Hegedus 
Dr. Martin Mackay
Celeste Mosby
Become a Member
